Caladrius Biosciences to Present at Upcoming October Conferences

BASKING RIDGE, N.J., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select therapeutic development pipeline, announces today that the Company’s leadership and experts will present at the following upcoming October conferences:

Cell and Gene Meeting on the Mesa

  • Website:
  • Venue: La Estancia, La Jolla, California
  • Session #1: Gene Therapy Manufacturing Workshop
  • Date and Time: Wednesday, October 5, 2016, 7:15 AM PT
  • Speaker: Robert Preti, PhD, Senior Vice President, Manufacturing and Technical Operations and Chief Technology Officer, Caladrius; President, PCT
  • Session #2: General Session
  • Date and Time: Wednesday, October 5, 2016, 9:00 AM PT
  • Speaker: Robert Preti, PhD
  • Session #3: Company Presentation on Caladrius Biosciences
  • Date and Time: Wednesday, October 5, 2016, 10:30 AM PT
  • Presenter: David Mazzo, PhD, Chief Executive Officer, Caladrius
  • Session #4: Process Improvement and Accelerated CMC Development Workshop
  • Date and Time: Thursday, October 6, 2016, 7:15 AM PT
  • Moderator: Robert Preti, PhD
  • Panel: Process Improvement and Comparability Assessment
  • Session #5: Forum For Innovative Regenerative Medicine Presentation & Moderated Interview
  • Date and Time: Thursday, October 6, 2016, 9:15 AM PT
  • Moderator: Robert Preti, PhD

Cell & Gene Therapy Bioprocessing & Commercialization

  • Date and Time: Thursday, October 6, 2016, 11:30 AM ET
  • Website:
  • Venue: Boston Convention and Exhibition Center, Boston, Massachusetts
  • Topic: Enabling the Cell Therapy Factory of the Future
  • Presenter: Brian Hampson, ME, Vice President, Global Manufacturing Sciences & Technology, PCT

Dawson James Small Cap Growth Conference

  • Date and Time: Thursday, October 20, 2016, 2:45 PM ET
  • Website:
  • Venue: Wyndham Grand Hotel, Jupiter, Florida
  • Topic: Company Presentation
  • Presenter: Joe Talamo, Chief Financial Officer, Caladrius
  • Webcast: Available at

The MicroCap Conference

About Caladrius Biosciences

Caladrius Biosciences, Inc. is advancing a proprietary platform technology for immunomodulation by pioneering the use of T regulatory cells as an innovative therapy for recent onset type 1 diabetes. The product candidate, CLBS03, is the subject of an ongoing Phase 2 clinical trial (The Sanford Project: T-Rex study) in collaboration with Sanford Research, and has been granted Orphan Drug and Fast Track designation by the U.S. Food and Drug Administration and Advanced Therapeutic Medicinal Product classification by the European Medicines Agency. The Company’s PCT subsidiary is a leading development and manufacturing partner to the cell therapy industry. PCT works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. PCT and Hitachi Chemical Co., Ltd. have entered into a strategic global collaboration to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise. For more information, visit

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2016, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.

CONTACTS: Investors: LHA Anne Marie Fields Senior Vice President Phone: +1-212-838-3777 Email: Media: Caladrius Biosciences, Inc. Eric Powers Director, Communications and Marketing Phone: +1-212-584-4173 Email:

Source:Caladrius Biosciences, Inc.